GLP-1 telehealth (women) · 2025

Best 5 GLP-1 telehealth brands for women — 2025

Historical snapshot — predates the 2026 compounding-pharmacy crackdown that changed the landscape for compounded providers.
Other years:2026 →Methodology: 8-axis rubric →

Editorial reconstruction — not a live 2025 audit. These 2025 rankings were reconstructed editorially using available historical pricing, FDA filings, and review records. They are not pulled from a live quarterly audit performed in 2025. Treat as approximate. For the current ranking, see GLP-1 telehealth (women) 2026 →

  1. Why: ABOM certification + insurance acceptance.

    Best for: Insured patients wanting specialist obesity medicine.

  2. Why: Physician-only model.

    Best for: Insured patients wanting MD prescriber.

  3. Why: HRT + GLP-1 in single platform.

    Best for: Post-menopause women.

  4. Why: Behavioral + GLP-1 combo. Strong app.

    Best for: Patients wanting structured program.

  5. Why: Affordable compounded option.

    Best for: Cash-pay patients wanting lower-cost access.

Frequently asked

Why is ABOM certification meaningful?

The American Board of Obesity Medicine (~7,000 certified physicians in US as of 2026) credentials clinicians specifically in obesity medicine. ABOM-credentialed prescribers handle GLP-1 protocols, side effects, a dose titration with deeper training than general primary care.

Is compounded GLP-1 safe?

Compounded semaglutide and tirzepatide are not FDA-reviewed for potency. FDA flagged quality concerns in 2024-2025. Brands ranked here that exclude compounded options (Form Health, Knownwell) are safer-default choices, particularly during the 2026 supply-chain transition period.

Will insurance cover GLP-1 for weight loss?

Some commercial plans cover Wegovy or Zepbound when BMI ≥30, or ≥27 with a comorbidity. Medicare currently does not cover GLP-1 for weight loss alone. The platforms ranked here with insurance expertise handle prior auth and appeals.

Other rankings

References

Regulatory + federal

  1. FDA. Medications containing semaglutide marketed for type 2 diabetes or weight loss. View source ↗ (accessed 2026-06-01)

Professional society guidelines

  1. American Board of Obesity Medicine. Diplomate directory. View source ↗ (accessed 2026-06-01)

Peer-reviewed research

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. View source ↗ (accessed 2026-06-01)
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. View source ↗ (accessed 2026-06-01)

Was this Best GLP-1 telehealth (women) ranking helpful?